Subject: (Copy) NIH Guide Vol. 19, No. 1, January 5, 1990, Part 1 (final,RFA
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Tue, 09 Jan 90 11:17 EST

Paul,
  Please post to the listserver as NIHGUIDE.010590.
    Thanks,
           Dottie
 ---------------------------- Text of forwarded message -----------------------
     
Subject: NIH Guide Vol. 19, No. 1, January 5, 1990, Part 1 (final,RFAs next)
X-comment: NIH Guide (including TOC) contained 13 pages (1040 lines)

     

     
     
Vol. 19, No. 1, January 5, 1990

                                   NOTICES

SUPPLEMENTS FOR UNDERREPRESENTED MINORITIES IN BIOMEDICAL AND
BEHAVIORAL RESEARCH SUPPORTED BY ADAMHA ............(84/261, 1044/1737)...... 1
Alcohol, Drug Abuse, and Mental Health Administration
Index:  ALCOHOL, DRUG ABUSE, MENTAL HEALTH

REVISIONS IN THE SALARY SCHEDULE FOR ADAMHA RESEARCH CAREER AWARDS .......... 3
Alcohol, Drug Abuse, and Mental Health Administration   (264/308)
Index:  ALCOHOL, DRUG ABUSE, MENTAL HEALTH

                     DATED ANNOUNCEMENTS (RFPs AND RFAs)

EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VIVO SCREENING ASSAYS
(RFP/MA) ...............................................(324/365)............ 4
National Cancer Institute
Index:  CANCER

ORGANIC CHEMICAL AND BIOCHEMICAL SYNTHESIS AND PHARMACOLOGICAL
FORMULATION OF CHEMOPREVENTIVE AGENTS (RFP/MA) .........(368/410)............ 4
National Cancer Institute
Index:  CANCER

EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MODELS (RFP/MA) ........ 5
National Cancer Institute                               (413/469)
Index:  CANCER

ASSIST CANCER PREVENTION (AMERICAN STOP SMOKING INTERVENTION STUDY
FOR CANCER PREVENTION) (RFP) ...........................(481/524)............ 6
National Cancer Institute
Index:  CANCER

CHILD HEALTH RESEARCH CENTERS (RFA 90-HD-03) ........(527/631, 1740/2340).... 6
National Institute of Child Health and Human Development
Index:  CHILD HEALTH, HUMAN DEVELOPMENT

SYNTHESIS OF COMPOUNDS FOR BORON NEUTRON CAPTURE THERAPY (RFA 90-CA-06) ..... 8
National Cancer Institute                            (641/726, 2341/2599)
Index:  CANCER

PRESCRIBE FOR HEALTH (RFA 90-CA-04) .................(729/835, 2600/3337).... 9
National Cancer Institute
Index:  CANCER

PLANNING AND DEVELOPMENT FOR PROTON THERAPY RESEARCH AND TREATMENT
FACILITIES (RFA 90-CA-07) ...........................(838/928, 3338/3628)....10
National Cancer Institute
Index:  CANCER

NATIONAL COOPERATIVE INNER-CITY ASTHMA STUDY (RFA 90-AI-02) ..(931/1000).....11
National Institute of Allergy and Infectious Diseases         (3629/4469)
Index:  ALLERGY, INFECTIOUS DISEASES

     

     
     
                                   NOTICES

SUPPLEMENTS FOR UNDERREPRESENTED MINORITIES IN BIOMEDICAL AND BEHAVIORAL
RESEARCH SUPPORTED BY ADAMHA
     
P.T. 34, FF; K.W. 0710030, 0404000, 1014006
     
Alcohol, Drug Abuse and Mental Health Administration
     
BACKGROUND
     
The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) currently
provides opportunities for minorities through regular research grant programs
of its component Institutes, National Institute on Drug Abuse (NIDA), National
Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute
of Mental Health (NIMH), and through other special initiatives.  The ADAMHA
recognizes the need to increase the number of underrepresented minority
scientists* participating in biomedical and behavioral research.
     
ADAMHA hereby notifies all Principal Investigators holding NIDA, NIAAA or NIMH
research grants of the availability of funds for administrative supplements
designed to provide a continuum of support for underrepresented minority
scientists and students.# These supplements may support research experience
for minority undergraduate students, graduate research assistants, and
minority investigators.  The aim of these programs is to attract and encourage
these minority individuals to pursue biomedical and behavioral research
careers in areas within the missions of all the awarding components of ADAMHA
by providing supplemental funds to ongoing research grants.
     
The ADAMHA anticipates that by providing these scientific opportunities at
specific points in the research career development of minorities, it will
substantially increase numbers of minorities in biomedical and behavioral
research holding ADAMHA grants.
     
* For the purpose of these announcements, underrepresented minority
investigators, hereinafter referred to simply as minorities, are defined as
individuals belonging to a particular ethnic or racial group which has been
determined by the grantee institution to be underrepresented in biomedical or
behavioral research.  Awards will be limited to citizens or noncitizen
nationals of the United States.  In awarding supplements, ADAMHA will give
priority to projects involving Black, Hispanic, Native Americans, Pacific
Islanders or other ethnic or racial group members who have been found to be
underrepresented in biomedical or behavioral research nationally.
     
# This program supersedes the Minority Research Program (Administrative
Supplements) of NIAAA and NIDA.
     
GENERAL PROVISIONS
     
In all cases, the proposed supplements must be to support research experience
which will be an integral part of the approved ongoing research of the parent
grant.  As part of this research experience, the minority individual must be
given the opportunity to interact with individuals on the parent grant, to
contribute intellectually to the research and to enhance his/her research
skills and knowledge regarding the particular area of biomedical or behavioral
science.  Furthermore, the Principal Investigator must demonstrate a
willingness and understanding that the purpose of the award is to enhance the
research capability of the minority student or faculty member, and that the
research experience is intended to provide opportunities for minority
individuals to develop as independent, competitive research investigators.
Awards will be made consistent with the goals of strengthening the existing
research program and the overall programmatic balance of the funding agency.
     
Specific information concerning eligibility, provisions, application
procedures, and review and award criteria for the individual programs is set
forth in "Guidelines for Supplements for Underrepresented Minorities in
Biomedical and Behavioral Research Supported by ADAMHA."  Copies of these
guidelines can be obtained from staff persons whose names appear at the end of
this announcement.
     
ELIGIBILITY
     
Any Principal Investigator at a domestic institution holding an active R01,
R18, R37, P01, P50, U01, or U10, which has a minimum of two years of research
support remaining at the time of a requested supplemental award, is eligible
to submit a request for an administrative supplement to the awarding component
of the parent grant.  The purpose of the request will be to support a minority
     
                   Vol. 19, No. 1, January 5, 1990 - Page 1
undergraduate student, graduate research assistant or faculty member to
participate in ongoing research projects.
     
APPLICATION PROCEDURES
     
A request for a supplement may be submitted at any time.  In making requests,
the grantee institution, on behalf of the Principal Investigator of the parent
grant and in cooperation with the minority individual, should submit the
request for supplemental funds directly to the project officer for the parent
grant.
     
REVIEW AND AWARD CRITERIA
     
The staff of the particular awarding component will review requests for
supplements using the following general criteria:  (1) the qualifications of
the minority individual including career goals, prior research training and
experience; (2) plans for the proposed research experience in the supplemental
request and its relationship to the parent grant; (3) assurance from the
Principal Investigator that the experience will enhance the research
potential, knowledge and/or skills of the minority individual; and (4)
assurance from the Principal Investigator that the activities of the minority
individual are an integral part of the project.
     
FUNDING
     
The decision to fund a supplement will take approximately four to six weeks
from the time the request is submitted.  Within the first budget period, funds
will be provided as an administrative supplement to the parent grant.  In
subsequent years, continued funding for the supplement always is contingent on
funding of the parent grant and cannot extend beyond the current
non-competitive segment of the parent grant.
     
1.  RESEARCH SUPPLEMENTS FOR MINORITY UNDERGRADUATE STUDENTS
     
This research grant supplement provides an opportunity for any minority
undergraduate student interested in biomedical or behavioral research to
conduct research at a research institution during the summer or other period,
apart from an academic program.  The student may be affiliated with either the
applicant institution or any other academic institution.
     
2.  RESEARCH SUPPLEMENTS FOR MINORITY GRADUATE RESEARCH ASSISTANTS
     
Any minority graduate student affiliated with the applicant institution who is
actively pursuing a doctoral degree in one of the biomedical or behavioral
sciences is eligible for consideration.
     
The objective of this program is to reach out to potential minority
researchers in biomedical and behavioral sciences and give them an opportunity
for further development of research capability leading to independence as a
researcher.
     
3.  RESEARCH SUPPLEMENTS FOR MINORITY INVESTIGATORS
     
These supplements provide either short or long-term research support for
minority faculty members to enhance their research skills leading to an
independent research career.  The minority investigator may be affiliated with
either the applicant institution or any other institution.  The investigator
must have a doctoral degree, be beyond the level of a research trainee and be
a member of the faculty with at least one year of postdoctoral experience.
     
The recipient must make at least a two-year commitment to the research
project.  The minority investigator may participate in the conduct of research
for several intensive periods (e.g., 3-5 months during each year) or at a
minimum of 30 percent effort throughout the year.  The maximum period of
support is 4 years.
     
INQUIRIES
     
Principal Investigators interested in participating in these programs are
encouraged to contact the awarding component project officer for the parent
grant.  For general information about the ADAMHA programs and initiatives for
underrepresented minorities in biomedical and behavioral research, please
contact the following staff person in the appropriate awarding component:

     

     
                   Vol. 19, No. 1, January 5, 1990 - Page 2
Delores L. Parron, Ph.D.
Associate Director for Special Populations
NIMH
5600 Fishers Lane, Room 17C-16
Rockville, Maryland  20857
Telephone:  (301) 443-2847
FAX:  (301) 443-6893
     
Ernestine Vanderveen, Ph.D.
Associate Director, Division of Basic Research
NIAAA
5600 Fishers Lane, Room 14C-20
Rockville, Maryland  20857
Telephone:  (301) 443-1273
     
Catherine Bell-Bolek
Associate Director for Special Populations Research
NIDA
5600 Fishers Lane, Room 10-105
Rockville, MD  20857
Telephone:  (301) 443-0441

REVISIONS IN THE SALARY SCHEDULE FOR ADAMHA RESEARCH CAREER AWARDS
     
P.T. 34; K.W. 1014006
     
Alcohol, Drug Abuse, and Mental Health Administration
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Mental Health
     
This is to provide notice of a change in the basis for calculating the
Alcohol, Drug Abuse, and Mental Health Administration's (ADAMHA's) salary
contribution on research career awards, beginning with awards made from Fiscal
Year 1990 funds.  This notice supersedes a notice which appeared in the NIH
Guide for Grants and Contracts (Vol.  18, No. 28) on August 18, 1989, and
pertains to the following funding mechanisms:
     
Research Scientist Development Award, Level I*         K01
Research Scientist Development Award, Level II         K02
Research Scientist Award                               K05
NIMH Academic Awards                                   K07
NIMH Clinical Investigator Award*                      K08
NIMH Physician Scientist Award*                        K11
Scientist Development Award for Clinicians             K20
Scientist Development Award                            K21
     
Based on the revised policy, ADAMHA's contribution to the salary will be
calculated using the following table:
     
     Base Institutional Salary     ADAMHA Contribution
     
     Up to $45,000                 100 Percent of the Base
                                   Institutional Salary
     
     $45,001-$60,000               $45,000
     
     $60,001 and Above             75 percent of the Base Institutional
                                   Salary up to a Maximum of
                                   $75,000
     
This policy is based on the assumption that awardees will make an essentially
"full-time" (at least 80 percent) commitment to research and research related
activities.  Therefore, no percentage time factor will be used to determine
the ADAMHA contribution to the candidate's salary.
     
* Note:  No new K01, K08, or K11 awards have been made since Fiscal Year 1989.

     

     

     

                   Vol. 19, No. 1, January 5, 1990 - Page 3
                     DATED ANNOUNCEMENTS (RFPs AND RFAs)

EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VIVO SCREENING ASSAYS
     
RFP/MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CN-05248-20
     
P.T. 34; K.W. 0740018, 0755010, 0715035
     
National Cancer Institute
     
Master Agreements will be awarded for contractors capable of conducting in
vivo screening studies in laboratory animals (primarily rats and mice) using
gavage and other routes of administration of designated chemopreventive agents
in animal models.  Contractors may utilize any carcinogenic mechanism that is
consistent with the Evaluation Criteria, such as the administration of
carcinogens, promoters, hormones, irradiation, cells, or other carcinogenic
agents.  This research will be performed under cost-reimbursement and/or
fixed-price Master Agreement Orders (MAOs).  Offerors will not be considered
eligible for award unless they can conduct specific individual MAOs in
accordance with the Food and Drug Administration Good Laboratory Practice
Regulations in facilities that are operated in compliance with the NIH Guide
for the Care and Use of Laboratory Animals, the Animal Welfare Act as
administered by the US Department of Agriculture, and the U.S. Government
Principles for Utilization and Care of Vertebrate Animals Used for Testing
Research and Training.  The purpose of this acquisition is to qualify
additional contractors to an existing pool of Master Agreement Holders.  There
are currently eight (8) qualified contractors in the pool.  The period of
performance of the Master Agreement pool runs through December 30, 1991, which
also would be the expiration date for new Master Agreement Holders.  It is
estimated that up to four (4) Task Orders per year will be issued pursuant to
the Master Agreement contracts.
     
Date of issuance of the RFP/Master Agreement Announcement will be
approximately January 8, 1990, and responses will be due by February 16, 1990.
     
Copies of RFP No. NCI-CN-05248-20 may be obtained by sending a written request
to:
     
Mr. Charles E. Lerner, Contract Specialist
National Institutes of Health
National Cancer Institute
Research Contracts Branch, PCCS
Executive Plaza South, Room 635
Bethesda, Maryland  20892

ORGANIC CHEMICAL AND BIOCHEMICAL SYNTHESIS AND PHARMACOLOGICAL FORMULATION OF
CHEMOPREVENTIVE AGENTS
     
RFP/MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CN-05250-20
     
P.T. 34; K.W. 0740018, 1003006, 1003012, 0710100
     
National Cancer Institute
     
Master Agreements will be awarded for contractors capable of operating a
laboratory for synthesis and/or formulation of chemopreventive agents
according to the four (4) task areas described as follows:  Task I--Synthesis
of bulk quantities of chemopreventive agents under GMP conditions for clinical
evaluation.  Task II--Synthesis and formulation of chemopreventive agents for
in vitro and in vivo screening, efficacy, and safety evaluations.  Task
III--Production of experimental and bulk GMP formulations and drug delivery
systems for chemopreventive agents.  Task IV--Preparation of radiolabeled
chemopreventive agents for preclinical and clinical studies.  Offerors must
submit a separate proposal for each task area but can submit proposals for any
or all of the above task areas.  All Master Agreement Holders in each pool
will be eligible to compete for Master Agreement Orders issued during the
period of performance.  The purpose of this acquisition is to qualify
additional contractors to an existing pool of Master Agreement Holders.
Currently there is only one qualified contractor in the pool.  The period of
performance of the Master Agreement pool runs through January 1995, which also
would be the expiration date for new Master Agreement Holders.  It is
estimated that up to four (4) Task Orders per year will be awarded in each
task area, per year.
     
Date of issuance of the RFP/Master Agreement Announcement will be
approximately January 12, 1990, and responses will be due by February 16,
1990.
                   Vol. 19, No. 1, January 5, 1990 - Page 4
Copies of RFP No. NCI-CN-05250-20 may be obtained by sending a written request
to:
     
Mr. Charles E. Lerner, Contract Specialist
National Institutes of Health
National Cancer Institute
Research Contracts Branch, NCI
Executive Plaza South, Room 635
Bethesda, Maryland  20892
Telephone:  (301) 496-8603

EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MODELS
     
RFP/MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CN-05249-20
     
P.T. 34; K.W. 0740018, 0755020, 0715035
     
National Cancer Institute
     
Master Agreements will be awarded for contractors capable of evaluating the
efficacy of various designated chemopreventive agents at several dose levels
in animal models and of refining and improving animal test models for
chemopreventive studies.  The emphasis of the activity will be to take initial
leads on designated agents and expand the data base as to the spectrum of
carcinogens, spectrum of target sites and range of species.  These agents
     
have previously been evaluated for chemopreventive activity in various in
vitro tests and in a limited number of in vivo studies.  However, before a
decision can be made as to their suitability for Phase I clinical trials,
their efficacy and bioavailability must be evaluated in various animal models.
Agents to be tested are potentially hazardous.  The animal model systems also
involve the use of carcinogens.  Laboratory practices shall be employed which
will maintain any element of risk to personnel at an absolute minimum.  Where
indicated, tissue and compound handling must be performed in (at least) Class
I laminar flow cabinets which must meet NIH specs for work with carcinogen
agents.  It shall be required that the animal facilities be maintained in
accordance with the NIH Guide for the Care and Use of Laboratory Animals, the
Animal Welfare Act as administered by the US Department of Agriculture, and
the U.S. Government Principles for Utilization and Care of Vertebrate Animals
Used for Testing Research and Training.  This research will be performed under
cost-reimbursement and/or fixed price Master Agreement Orders (MAOs).
Offerors will not be considered eligible for award unless they can conduct
specific individual MAOs in accordance with the Food and Drug Administration
Good Laboratory Practice Regulations.  The contractor must have all the
equipment necessary to accomplish the studies including, but not limited to,
animal racks and caging, hazardous chemical storage cabinets and
refrigerators, pathology equipment such as microscopes and microtomes and
miscellaneous laboratory equipment.  The laboratory shall have or have access
to appropriate terminal and computer facilities and equipment for data
collection and storage.  The purpose of this acquisition is to qualify
additional contractors to an existing pool of Master Agreement Holders.
Currently eight (8) qualified contractors are in the pool.  The period of
performance of the Master Agreement pool runs through August 19, 1993, which
also would be the expiration date for new Master Agreement Holders.  It is
estimated that up to four (4) Task Orders per year will be issued pursuant to
the Master Agreement Contracts.
     
Date of issuance of the RFP/Master Agreement Announcement will be
approximately January 8, 1990, and responses will be due by February 16, 1990.
     
Copies of RFP no.  NCI-CN-05249-20 may be obtained by sending a written
request to:
     
Mr. Charles E. Lerner, Contract Specialist
Research Contracts Branch, PCCS
Executive Plaza South, Room 635
Bethesda, Maryland  20892
Telephone:  (301) 496-8603

     

     

     
     
                   Vol. 19, No. 1, January 5, 1990 - Page 5
ASSIST CANCER PREVENTION (AMERICAN STOP SMOKING INTERVENTION STUDY FOR CANCER
PREVENTION)
     
RFP AVAILABLE:  NCI-CN-95165-38
     
P.T. 34; K.W. 0404019, 0745027
     
National Cancer Institute
     
The goal of this acquisition is to apply a specific set of proven
state-of-the-art smoking prevention and control interventions developed in
randomized research trials throughout approximately twenty demonstration
sites.  These sites will form the framework through which to implement and
institutionalize these intervention strategies in order to reduce smoking
prevalence.  This framework will comprise a coalition of community and
state-level organizations and agencies which have the capacity and/or the
mandate to reach smokers and youth at risk of becoming smokers.  The proposed
RFP will restrict competition to health departments in States or large
metropolitan areas which have the capability to meet the government
requirements in cooperation with a voluntary health agency.  The statutory
authorities used to justify the limited field of competition are 41 U.S.C.
253(c) (3) and FAR 6.302-3.  FAR 6.302.3(a) (2) states:  "Full and open
competition need not be provided for when it is necessary to award the
contract to a particular source or sources in order...(ii) to establish or
maintain an essential engineering, research or development capability to be
provided by an educational or other non-profit institution...". The FAR goes
on to cite appropriate use of this exception when it is necessary to
"Establish or maintain an essential capability for...  developmental work
calling for the practical application of investigative findings and theories
of a scientific or technical nature."  Twenty awards are anticipated for
6.5-year incrementally funded cost-reimbursement completion contracts.
     
RFP No. NCI-CN-95165-38 is now available and proposals will be due
approximately September 25, 1990.
     
Copies of the RFP may be obtained by sending a written request to:
     
Ms. Barbara Mercer, Contracting Officer
National Institutes of Health
National Cancer Institute
Research Contracts Branch, PCCS
Executive Plaza South, Room 635
Bethesda, Maryland  20892
Telephone:  (301) 496-8603

CHILD HEALTH RESEARCH CENTERS
     
RFA AVAILABLE:  90-HD-03
     
P.T. 04; K.W. 0770005, 0785170, 0710030
     
National Institute of Child Health and Human Development
     
Application Receipt Date:  April 23, 1990
     
The National Institute of Child Health and Human Development (NICHD) invites
Center Core Grant applications for a new program of Child Health Research
Centers (CHRC).  These Centers are intended to provide resources to speed the
transfer of knowledge gained through studies in basic science to clinical
applications which will benefit the health of children.  This is to be
accomplished by increasing the number and effectiveness of pediatric
investigators who have a research grounding in basic science, and to stimulate
and facilitate the application of their skills to research on pressing
pediatric problems.
     
Background
     
The past few years have seen unprecedented advances in the power and speed of
basic science methods applicable to investigations of inherited and acquired
disease.  There is a need for researchers who are skilled with these methods
and interested in applying them to clinical problems in pediatrics.  The NICHD
intends to help meet this need by establishing Centers in which nascent
pediatric investigators can develop the appropriate technological expertise.

     

                   Vol. 19, No. 1, January 5, 1990 - Page 6
Objectives and Scope
     
Under the aegis of a CHRC grant an institution identifies for development a
scientific area or theme that is relevant to the pediatric research mission of
the NICHD.  Established investigators whose research is already funded by NIH
or other competitively reviewed grants or contracts combine to establish in
their institution a center of excellence in the chosen subject area.
Individuals with a wide range of scientific backgrounds, especially those with
basic science orientation, are thus encouraged to interact with each other and
with newly trained pediatricians just embarking on their research careers.  A
shared core laboratory, which provides services to complement and extend the
capabilities of the established investigators to facilitate the career
development of new investigators, is also a part of the Center.  The
established investigators make available their expertise and laboratory
facilities, which together with the shared core laboratory comprise the
laboratory resources of the Center, to be utilized by junior investigators for
new research projects which will enhance their basic science knowledge and
skills.  Support for conducting these projects is provided by the Center.
     
The CHRC grant may provide funds for three purposes:
     
1.  Administration of the Center.
     
2.  Improvements in the child health-related research program of an
institution in an area of scientific excellence through the establishment and
maintenance of a shared core laboratory.
     
3.  Support for new projects, conducted by junior investigators, designed to
enhance their research skills and produce preliminary data which could lead to
successful competitive grant applications to the NIH or other agencies.
     
The novel feature of these grants is the flexibility in the use of the funds
awarded for research support and career development, so that decisions about
which new projects and which junior investigators are to be supported are made
by the grantee institution.  Competing continuation of a CHRC grant is
contingent on demonstration of good judgment in these decisions, as indicated
by scientific progress, success in the initiation of new
competitively-supported research grants and contracts, and the development of
new pediatric investigators.
     
Investigators are encouraged to include minorities and women in their study
populations if human subjects are to be involved in the research.
     
Mechanisms of Support
     
The mechanism for funding of these Centers is the P30 grant, which provides
core support for laboratories and administrative resources applicable to a
number of different research projects.  Awards are for five years, at a
maximum level of $400,000 (direct plus indirect cost) annually, and are
renewable.  Awards are not subject to periodic increases for inflation.  It is
anticipated that five to seven meritorious applications will be funded under
this program.
     
Application Procedure
     
Applications must be submitted on form PHS-398 (rev.  10/88).  Detailed
instructions for application are available as additional information.
     
Additional Information
     
Potential applicants should request detailed information about CHRC grants
before preparing an application.  Information is available from:
     
Ephraim Y. Levin, M.D.
Medical Officer
Endocrinology, Nutrition and Growth Branch
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
Room 637, Executive Plaza North
Bethesda, Maryland  20892
Telephone:  (301) 496-5593

     

     

                   Vol. 19, No. 1, January 5, 1990 - Page 7
SYNTHESIS OF COMPOUNDS FOR BORON NEUTRON CAPTURE THERAPY
     
RFA AVAILABLE:  90-CA-06
     
P.T. 34; K.W. 1003006, 1013026, 0785190
     
National Cancer Institute
     
Letter of Intent Receipt Date:  March 1, 1990
Application Receipt Date:  April 4, 1990
     
The Radiation Research Program (RRP), Division of Cancer Treatment (DCT), of
the National Cancer Institute (NCI), announces the availability of a Request
For Applications (RFA) to synthesize boronated compounds for the clinical
application of Boron Neutron Capture Therapy.
     
BACKGROUND
     
Boron Neutron Capture Therapy (BNCT) is a potential treatment modality for
cancerous tumors, based on the nuclear reaction that occurs when a
non-radioactive isotope of boron (10B) is irradiated and absorbs low energy
(thermal) neutrons.  The unstable boron (11B) that is formed undergoes
instantaneous nuclear fission to yield a lithium (7Li) nucleus and a highly
energetic alpha particle.  Theoretically, a single alpha particle can kill a
cancer cell if part of its energy is released in the nucleus.  The rationale
for using BNCT is to exploit the short range of the alpha particle.  If boron
(10B) atoms could be selectively concentrated in the tumor, then the
subsequent irradiation of the tumor would minimize the radiation dose to the
normal tissue.
     
RESEARCH GOALS AND SCOPE
     
The overall goal of this solicitation is to synthesize boron containing
compounds which have a high probability of preferentially localizing in tumor
cells rather than normal tissues and/or are rapidly cleared from normal
tissues and blood but retained by tumor tissues.  These properties would
produce high tumor to normal tissue ratios and high tumor to blood ratios,
characteristics that would make these compounds ideal for use in BNCT.
Current knowledge of tumor receptors, uptake mechanisms, etc., make it
realistic to consider the development and synthesis of site-specific compounds
for BNCT.  Therefore, consideration should be given to coupling boron to
compounds which have a known affinity to tumors.  Multiple discipline
approaches may be needed to achieve the research goals of this solicitation.
     
MECHANISM OF SUPPORT
     
Support of these awards resulting from this RFA will be through the National
Institutes of Health (NIH) grant-in-aid (RO1).  This RFA is a one-time
solicitation.  Approximately $475,000 in total costs per year for five (5)
years will be committed to specifically fund applications which are submitted
in response to this RFA.  It is anticipated that 3 to 4 awards will be made,
depending on the receipt of a sufficient number of applications of high
scientific merit.  The total project period for applications submitted in
response to the present RFA should not exceed 5 years.  The earliest feasible
start date for the initial awards will be April 1, 1991.  The award of grants
pursuant to this RFA is also contingent upon the availability of funds for
this purpose.
     
ELIGIBILITY REQUIREMENT
     
Profit and non-profit, domestic and foreign organizations are eligible to
apply unless specifically excluded by legislation.  All applicants need to
have the personnel, equipment and facilities to synthesize and characterize
the compounds requested.  Compounds submitted have to be single chemical
entities.
     
INQUIRIES
     
Written or telephone inquiries concerning the objectives and scope of this RFA
are encouraged, as are inquiries about whether or not specific proposed
research would be responsive.  They should be directed to the Program
Director, at the address below.  The program director welcomes the opportunity
to clarify any issues or questions from potential applicants.

     

     
                   Vol. 19, No. 1, January 5, 1990 - Page 8
Thomas A. Strike, Ph.D.
Radiation Research Program
National Cancer Institute
9000 Rockville Pike, EPN Room 800
Bethesda, Maryland  20892
Telephone:  (301) 496-9360

PRESCRIBE FOR HEALTH
     
RFA AVAILABLE:  90-CA-04
     
P.T. 34; K.W. 0715035, 0745020, 0403004
     
National Cancer Institute
     
Letter of Intent Receipt Date:  February 9, 1990
Application Receipt Date:   June 13, 1990
     
I. INTRODUCTION
     
The Division of Cancer Prevention and Control (DCPC) invites applications for
intervention studies to accelerate the diffusion of the National Cancer
Institute (NCI) Working Guidelines for Early Cancer Detection into primary
care medical practices through intermediary organizations.  An intermediary
organization is defined as an organization employing, reimbursing, training,
licensing, and/or certifying physicians in primary care practice, or an
established professional association of physicians.
     
Through the interventions studies resulting from this RFA, DCPC anticipates
that interventions will be identified to improve the adoption, maintenance,
quality, and dissemination of early cancer detection regimens in primary care
practice.
     
II.  RESEARCH GOALS AND SCOPE
     
Overview
     
The goal of this RFA is to demonstrate that intermediary organizations can
effectively diffuse early cancer detection regimens to primary care medical
practices.  The specific objectives are:
     
  o  To test the effectiveness of intermediary organizations in
     accelerating and increasing the adoption of early cancer detection
     regimens by primary care practices;
     
  o  To test the effectiveness of these interventions in improving the
     maintenance of early cancer detection regimens by primary care
     practices;
     
  o  To test the effectiveness of these interventions in improving the
     quality of implementation of early cancer detection regimens by
     primary care practices.
     
Interventions
     
Applicants will propose interventions that build creatively upon the existing
research base in physician behavior change, including consideration of
barriers to the delivery of preventive services.  At least four early
detection guidelines are to be addressed.  Priority will be given to projects
that show potential for being sustainable beyond the period of NCI funding.
Evidence of the commitment of the intermediary organization to the research
project and the organization's potential for influencing the practices of
affiliated primary care physicians is strongly recommended.
     
Design and Evaluation
     
Measuring changes in the performance of physicians is an important challenge
in this program.  Applicants should provide for a sample size of primary care
practices adequate to detect desired behavioral changes over time.
Randomization of primary care practices to intervention and control groups is
the preferred design, although other well justified designs will be
considered.  Collaborative arrangements are encouraged.  The applicant should
document the commitment of primary care practices to participate in the
project, including practices serving low income and minority populations.

     
     
                   Vol. 19, No. 1, January 5, 1990 - Page 9
III.  MECHANISM OF SUPPORT
     
This RFA will use the National Institutes of Health grant-in-aid (RO1).
Approximately $1,200,000 in total costs per year for 4 years will be committed
to specifically fund applications which are submitted in response to this RFA.
A total of three or more awards may be made.  The project time period should
not exceed 4 years.  The earliest feasible start date for the initial awards
will be December 1, 1990.
     
IV.  INQUIRIES
     
A copy of the complete RFA describing the research goals and scope, the review
criteria, and the method of applying can be obtained by contacting:
     
Suzanne Haynes, Ph.D.
Program Director
Chief, Health Promotion Sciences Branch
EPN Building, Room 241
9000 Rockville Pike
Bethesda, Maryland 20892-4200
Telephone:  (301) 496-0273
     
or:
     
Charles R. Smart, M.D.
Chief, Early Detection Branch
EPN Building, Room 305
9000 Rockville Pike
Bethesda, Maryland  20892-4200
Telephone:  (301) 496-8544
     
Written or telephone inquiries concerning the objectives and scope of this RFA
or inquiries about whether or not specific proposed research would be
responsive are encouraged.  The NCI staff welcomes the opportunity to clarify
any issues or questions from potential applicants.

PLANNING AND DEVELOPMENT FOR PROTON THERAPY RESEARCH AND TREATMENT FACILITIES
     
RFA AVAILABLE:  90-CA-07
     
P.T. 34; K.W. 0715035, 1013026, 0785190, 0745070
     
National Cancer Institute
     
Letter of Intent Receipt Date:  February 22, 1990
Application Receipt Date:  March 22, 1990
     
INTRODUCTION
     
The Radiation Research Program (RRP), Division of Cancer Treatment (DCT) of
the National Cancer Institute (NCI) invites grant applications from interested
investigators for planning and development for proton therapy research and
treatment facilities.
     
BACKGROUND INFORMATION
     
The potential advantage of proton therapy over x-ray therapy was hypothesized
in 1947.  Since then, approximately 7500 patients have been treated worldwide.
The entire world experience with protons has confirmed the expectation that
for appropriately selected tumor sites, higher doses to a target volume and
smaller treatment volumes can be achieved with protons than with x-rays.
Available data indicate that this has resulted in a higher tumor control
frequency, comparable or less morbidity, and no increase in marginal failures.
There are many years of worthwhile research yet to be done to determine the
full role of proton radiation therapy.  This translates into a need for a
small number (2-3) of state-of-the-art, hospital optimized, dedicated proton
research and treatment facilities in the U.S. In recognition of this fact, the
U.S. Congress has provided, in the 1990 NCI budget, $1.5 million for planning
and development of such facilities.
     
RESEARCH GOALS AND SCOPE
     
The ultimate goal of this solicitation is to stimulate a process of planning
and development which, on the scale of approximately five years, will result
in the establishment of a small number of proton beam research and treatment
centers, funded primarily from private sources.  The immediate goal of this
solicitation is to support one to three Exploratory/Developmental grants
     
                  Vol. 19, No. 1, January 5, 1990 - Page 10
(R21's) to conduct planning and development activities for proton therapy
research and treatment centers.
     
The Request for Applications (RFA) will be a one-time solicitation.  However,
should the NCI determine that there is a sufficient continuing program need, a
request for renewal applications will be announced.  Only recipients of awards
under this RFA will be eligible to apply.
     
Approximately $1,500,000 in total costs for one (1) year will be committed to
specifically fund applications which are submitted in response to this RFA.
It is anticipated that 1 to 3 awards will be made.  In order to preserve the
intent of Congress, no individual award will exceed $750,000 total cost.  The
total project period for applications should not exceed 1 year.  The earliest
feasible start date for the awards will be September 15, 1990.
     
Only domestic institutions and organizations, and government agencies are
eligible to apply.
     
INQUIRIES
     
A copy of the complete RFA describing the research goals and scope, the review
criteria and method of applying can be obtained by contacting:
     
Francis J. Mahoney, Ph.D.
Radiation Research Program
Division of Cancer Treatment
National Cancer Institute
EPN 800
Bethesda, Maryland  20892
Telephone:  (301) 496-9360
     
Written or telephone inquiries concerning the objectives and scope of this RFA
or inquiries about whether specific proposed research would be responsive are
encouraged and should be directed to Dr. Mahoney at the above address.
     
LETTER OF INTENT
     
Prospective applicants are asked to submit, by February 22, 1990, a letter of
intent that includes a descriptive title of the proposed planning and
development effort, the name and address of the principal investigator, the
names of other key personnel, the participating institutions, and the number
and title of the RFA in response to which the application is being submitted.
     
Although the letter of intent is important to NCI staff for planning purposes,
it is not required, is not binding, and does not enter into the review of the
subsequent application.
     
The letter of intent should be sent to Dr. Mahoney at the above address.

NATIONAL COOPERATIVE INNER-CITY ASTHMA STUDY
     
RFA AVAILABLE:  90-AI-02
     
P.T. 34; K.W. 0715013, 0755015
     
National Institute of Allergy and Infectious Diseases
     
Letter of Intent Date:     February 15, 1990
Application Receipt Date:  March 23, 1990
     
The National Institute of Allergy and Infectious Diseases (NIAID), through the
Asthma and Allergy Branch (AAB) of the Division of Allergy, Immunology, and
Transplantation (DAIT) and the Epidemiology and Biometry Branch (EBB) of the
Division of Microbiology and Infectious Diseases (DMID), invites applications
from investigators willing to participate under Cooperative Agreements in a
two phase multi-center cooperative clinical trial.  The goal of this study is
to design and evaluate a comprehensive intervention program to reduce asthma
related morbidity for Black and Hispanic children residing in the inner city.
     
The study will be composed of two phases.  The objective of the first phase is
to elucidate those factors that are contributing to asthma morbidity for
children in the targeted population.  The objective of the second phase is to
develop, implement, and evaluate a feasible clinical intervention program to
achieve long-term reduction in asthma morbidity for the children residing in
the inner city.  The information gained from Phase I will be used to implement
Phase II.

                  Vol. 19, No. 1, January 5, 1990 - Page 11
In order to effectively meet the stated objectives, a network of centers will
be established to conduct research using common protocols thus facilitating
the study of large numbers of patients in a shorter time-frame than would be
possible were individual centers to act alone.
     
The benefit of this activity will be to the public, including:  inner city
Black and Hispanic children, children with asthma, their families, and their
health-care providers.
     
Successful applicant(s) funded under this Request for Applications (RFA) will
be supported through Cooperative Agreements.  Cooperative Agreements are
grants awarded to both not-for-profit and for-profit organizations and
institutions.  This type of solicitation is utilized when it is desired to
encourage investigator-initiated research projects in areas of special
importance to the National Institutes of Health and where substantial
programmatic involvement by staff is anticipated.  This RFA solicitation
represents a single competition, with a specified deadline for receipt of
applications.  There are no present plans to reissue this request for
applications at any future time.  The NIAID may invite competitive renewal
applications upon expiration of the initial funding period, contingent on the
continued availability of funds for this purpose, and the continued need to
stimulate research in this area.  All applications received in response to the
RFA will be reviewed by the same Initial Review Group (IRG) convened by the
NIAID and by the National Advisory Allergy and Infectious Diseases Council.
The deadline for the receipt of applications in response to this RFA is March
23, 1990.  Applications should be prepared and submitted in accordance with
the aims and requirements as set forth in the detailed version of the RFA.
     
NIAID has set aside $1,000,000 total costs for funding the initial year.
     
For a copy of the complete RFA, please contact:
     
Lawrence J. Prograis, Jr., M.D.
Chief, Asthma and Allergy Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 752
National Institutes of Health
Bethesda, Maryland  20892
Telephone:  (301) 496-8973

     

     

     

     

     

     

     

     

     

     

     

     

     
                  Vol. 19, No. 1, January 5, 1990 - Page 12